Literature DB >> 3492542

The cyclosporins inhibit lymphocyte activation at more than one site.

E W Gelfand, R K Cheung, G B Mills.   

Abstract

Cyclosporin A (CsA), a potent immunosuppressive agent, acts primarily by inhibiting T cell function. Although several potential sites of action have been identified, the mechanisms whereby CsA mediates its immunosuppressive properties have not been fully delineated. We have examined the effects of the immunosuppressive cyclosporins, CsA, dihydrocyclosporin D, and cyclosporin G, and a nonimmunosuppressive analog, cyclosporin H, on early events associated with activation of human T cells. Interleukin 2 (IL 2) receptor expression, as measured by immunofluorescence, was unaffected by CsA. Despite this, in the continuous presence of CsA, exogenous IL 2 did not bypass CsA inhibition of phytohemagglutinin (PHA)-induced proliferation. Thus, one site of activity of CsA is on IL 2-induced proliferation of IL 2 receptor-expressing cells. In addition, several potential mechanisms for inhibiting IL 2 secretion were identified. Changes in cytosolic free Ca2+ ([Ca2+]i), an obligatory event for PHA-induced IL 2 secretion, were inhibited by a 30-min preincubation with the immunosuppressive cyclosporins but not the inactive analog. In this action, the drug effects cannot be distinguished from that of Ca2+ channel blockers. The active compounds also resulted in membrane depolarization, an effect which may, in part, explain the reduction in PHA-induced changes in [Ca2+]i. These results identify multiple sites of action of the immunosuppressive cyclosporins, the combination of which likely accounts for their selective inhibition of T cell function in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492542

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Effects of cyclosporins and transforming growth factor beta 1 on thyroid hormone action in cultured fetal rat limb bones.

Authors:  P Lakatos; P H Stern
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

2.  Synergism between AS101 and PMA in lymphokine production.

Authors:  B Sredni; Y Kalechman; F Shalit; M Albeck
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

3.  Calcineurin Inhibitors and Variation in the Performance of Interferon-γ Release Assays Used to Detect Tuberculosis Infection.

Authors:  Edward Barton; Yifang Gao; Darran Ball; Katy Fidler; Nigel Klein; Nigel Curtis; Vanessa Clifford; Ben G Marshall; Andrew Chancellor; Salah Mansour; Paul Elkington; Marc Tebruegge
Journal:  Ann Am Thorac Soc       Date:  2019-06

4.  Single strand DNA breaks in mitogen stimulated T lymphocytes are religated by a mechanism independent of accessory cells.

Authors:  D J Harrison; A M Crowe; A H Wyllie
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

5.  Cyclosporin A prevents the in vivo development of murine prothymocytes from uncommitted (Thy-1-) precursor cells.

Authors:  R D Huby; G Janossy; I A Lampert
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

6.  Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.

Authors:  B M Foxwell; J Simon; J J Herrero; D Taylor; G Woerly; D Cantrell; B Ryffel
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

7.  In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains.

Authors:  S Caillat-Zucman; L Chatenoud; J F Bach
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

8.  Oral administration of cyclosporin does not prevent expansion of antigen-specific, gut-associated, and spleen lymphocyte populations during Chlamydia trachomatis proctitis in nonhuman primates.

Authors:  M Zeitz; T C Quinn; A S Graeff; R Schwarting; S P James
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

9.  Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action.

Authors:  D Yasutomi; C Odaka; S Saito; H Niizeki; H Kizaki; T Tadakuma
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.